Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia (CML), patients generally must take them for the rest of their lives and may cease benefiting from them over time. In ...
Sep 15, 2016
0
56
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...
Sep 26, 2017
0
26
A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.
Mar 18, 2012
0
0
Investigators have found that dasatinib, a drug commonly used to treat chronic myeloid leukemia, is strongly associated with kidney injury.
Sep 12, 2023
0
9
The protective microenvironment of the hematopoietic stem cell niche, which produces cells of the blood and the immune system, also protects against myeloproliferative neoplasia.
Jun 22, 2014
0
0
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered that a protein produced by a cancer gene leads to the development of a deadly, late-stage form of prostate ...
Apr 1, 2016
0
6
A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown—role in the development and progression of acute myeloid leukemia (AML), a fast-growing ...
Jul 23, 2015
0
21
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about some of the most common types of these two diseases.
Sep 3, 2021
0
2
University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today—an inability to get patients off treatment.
Feb 16, 2016
1
58
